星标 ★ IPO日报 精彩文章第一时间推送 9月8日晚间，北京浩丰创源科技股份有限公司（以下简称"ST浩丰"，300419）发布公告，公司控股股东北京华软鑫创实业发展有限公司 （以下简称"华软实业"）及实际控制人王广宇正在筹划公司控制权变更相关事宜，可能导致公司控股股东和实际控制人发生变更。 为避免公司股价异常波动，维护投资者利益，公司申请自2025年9月9日开市起停牌，预计停牌时间不超过2个交易日。 张力制图 再次变更控股权 资料显示，ST浩丰2015年上市，主要聚焦在智能金融、智能安全、智能商业等业务领域。 截至最新披露，华软实业持有公司股份5518万股，持股比例为15%，是公司的控股股东，王广宇为公司的实际控制人。 IPO日报发现，华软实业是在四年前成为了公司的控股股东。 也就是说，如果本次交易成功，这是公司上市以来，第二次控制权变更。 2021年9月，浩丰科技的原控股股东、实际控制人孙成文与华软实业签订了《股份转让协议》，孙成文以10.88元/股的价格通过协议转让的方 式向华软实业转让其直接持有的浩丰科技5518万股股份（占上市公司总股本的15.0046%），转让价款总额为6亿元。 ST浩丰不久前公布 ...

星标 ★ IPO日报 精彩文章第一时间推送 制图：佘诗婕 笔者认为，就市场数据来看，当前由于流动性充足，其他板块有望迎来相关资金的关注。比如说固态电池、消 费电子、机器人、猪肉、酒类以及其他滞涨板块。 而"易中天"的表现说明，涨多了的股票依然可能继续下 跌，现在接盘的投资者或许面临接在半山腰的风险。 笔者以为， 总体来看，大盘似乎有在此企稳之意，沪可能3800点左右来回震荡消化，在此构筑一个3800点 为轴的箱体，这个可能性或许不小。 当然，这只是一个假设，是否如此，明天后天可以验证。 我们再来看看今天市场的一些关键数据，上涨家数3957，下跌家数1350，成交量24631亿元，相比上一个交 易日多了约1148亿元。连板股方面：7家2板、3家3板、1家4板，0家5板以上，最高板为首开股份。打板的 赚钱效应2.6%，炸板率26%。总体来看，赚钱效应一般。 目前来看，板块持续性较好的为固态电池和机器人。 从成交量来看，今天有2.4万多亿元，相比上一个交易日放量了一千多亿元，不过值得注意的是，上一个交易 日，场内资金是流入的，而今天场内资金继续上上个交易日之前的趋势，流出近600亿元，说明场内资金依然 把此位置看作 ...

星标 ★ IPO日报 精彩文章第一时间推送 9月7日晚间，浙江向日葵大健康科技股份有限公司（以下简称"向日葵"，SZ300111）公告称，公司正在筹划以发行股份及 （或）支付现金的方式收购漳州兮璞材料科技有限公司（以下简称"兮璞材料"）的控股权及浙江贝得药业有限公司（以下简称"贝 得药业"）40%股权，同时拟募集配套资金。 本次交易尚处于筹划阶段，截至最新披露，兮璞材料及贝得药业的估值尚未最终确定。经初步测算，本次交易预计构成《上市公司 重大资产重组管理办法》规定的重大资产重组。本次交易不会导致公司实际控制人发生变更，不构成重组上市。 制图：佘诗婕 未完成业绩承诺 若交易完成，贝得药业将成为向日葵的全资子公司。 需要指出的是，向日葵目前持有的贝得药业60%股权，就是在2019年收购而来。 彼时，向日葵的主营业务为大规格高效晶体硅太阳能电池及组件的生产、销售。但当时，受国外对来自中国的光伏产品开展反倾 销、反补贴调查，以及国内调控光伏电站及分布式光伏项目指标、调整上网电价及补贴标准等因素影响，公司盈利水平波动较大。 公司认为，医药行业受到国家产业政策的大力支持，市场潜力巨大，周期性相对较弱。基于此，向日葵最初拟 ...

星标 ★ IPO日报 精彩文章第一时间推送 9月3日，港交所官网披露，广东金晟新能源股份有限公司（下称"金晟新能"）向港交所主板提交上市申请，中 金公司和招银国际为其联席保荐人。 公司继此前2022年启动深交所上市辅导、2024年12月20日向港交所递交上市申请失效后，这次第三次谋求上 市。 IPO日报注意到，接连三次闯关的金晟新能近年来收入持续下滑，净利润三年半累计亏损8.08亿元，且亏损持续 扩大。 制图：佘诗婕 累亏8.08亿 金晟新能是锂电池回收及再生利用解决方案提供商，提供一系列再生利用产品，主要包括碳酸锂、硫酸镍及硫酸 钴，公司的产品在下游被广泛用于电动汽车、储能系统和消费电子产品等锂电池主流应用场景，形成了全面且垂 直整合的业务模式、产业链条完整的产业闭环。 根据咨询机构弗若斯特沙利文报告，以2024年再生利用销售收入计，金晟新能是全球第二大的锂电池回收及再 生利用企业，公司也是全球第一大的第三方锂电池回收及再生利用企业。 2022年-2024年及2025年上半年（下称"报告期"），金晟新能实现收入分别约为29.05亿元、28.92亿元、 21.57亿元、9.37亿元，持续下滑，今年上半年同比减 ...

Core Viewpoint - The control change of Zhonghuan Hailu has been terminated after only one week of planning due to a lack of consensus between the controlling shareholder and the transaction party regarding the company's future development arrangements [2][3]. Summary by Sections Control Change Announcement - On August 28, Zhonghuan Hailu announced that its controlling shareholder, Wu Junshan, was planning a change in control, which could lead to a change in the actual controller [3]. - The stock was suspended from trading starting August 29, with an expected resumption within two trading days [3]. Termination of Control Change - The termination of the control change was announced on September 4, with the company stating that it would not adversely affect its production and operational activities or future development strategies [2][4]. - The entire process from the initial announcement to termination took only one week [4]. Stock Performance - Following the announcement of the termination, Zhonghuan Hailu's stock hit the daily limit down, closing at 31.68 yuan [3]. - The stock had previously surged from approximately 11.5 yuan at the beginning of the year to a closing price of 39.6 yuan, representing a nearly 250% increase [4]. Financial Performance - Since its listing in 2021, Zhonghuan Hailu has experienced a continuous decline in revenue and net profit, with a shift from profit to loss starting in 2023 [4]. - The company's revenue from 2020 to 2024 was 1.097 billion, 1.069 billion, 1.042 billion, 625 million, and 579 million yuan, respectively, while net profits were 134 million, 72 million, 40 million, -32 million, and -154 million yuan [4].

星标 ★ IPO日报 精彩文章第一时间推送 9月4日晚间，中成进出口股份有限公司（简称"中成股份"，000151.SZ）披露了重组预案。 公告显示，中成股份拟发行股份购买中国技术进出口集团有限公司（简称"中技进出口"）持有的中技江苏清洁能源有限公司（简称"中技江苏"）100%股 权，交易价格1.51亿元；同时，公司拟同步募集配套资金不超过1.51亿元，扣除发行费用后将用于标的公司通用技术东莞基站节电服务二期项目、补充流 动资金。 本次交易的交易对方中技进出口为上市公司间接控股股东通用技术集团控制的企业。根据《重组管理办法》和《股票上市规则》，公司本次交易构成关联 交易。 张力制图 依赖宁德时代 据悉，中技江苏主要从事工商业用户侧储能项目的投资、开发和运营，主要产品为合同能源管理服务，向用户提供必要的储能、充放电等服务，以达到节 省用户能源成本的效果。 截至目前，标的公司共有7个已运营项目、1个在建项目、1个拟建项目，在运营的储能电站主要位于江苏省溧阳市、广东省东莞市、广东省肇庆市、广东 省广州市、河南省济源市。 财务数据方面，2023年—2024年以及2025年上半年，标的公司的营业收入分别为1539.96万 ...

Market Overview - On September 4, the market experienced a significant decline, with the ChiNext index dropping over 5 points and the Shenzhen index falling over 4 points, indicating a panic sell-off across the board [3][4] - The "Cold King" (Hanwang Technology) led the decline with a drop of 14.45%, closing at 1202 yuan, down nearly 200 yuan from its intraday high of 1389 yuan [3] Trading Data - The trading day saw 2297 stocks rise and 2990 stocks fall, with a total trading volume of 25.819 trillion yuan, an increase of approximately 1.862 trillion yuan compared to the previous day [4] - Despite the increase in trading volume, there was a net outflow of 122.9 billion yuan, indicating that profit-taking was still prevalent among investors [4] Technical Analysis - The Shanghai Composite Index broke below the 20-day moving average, suggesting a potential for further declines, while the ChiNext index fell below the 10-day moving average [3][4] - The market is currently experiencing a normal adjustment phase, with the potential for a short-term bottoming period if the downward trend can be halted [5] Investor Sentiment - The current market sentiment is cautious, with investors advised to protect their capital and wait for new market leaders to emerge [5] - The overall market liquidity remains good, with a trading volume exceeding 2.5 trillion yuan, indicating that there is still money in the market despite the recent downturn [5]

星标 ★ IPO日报 精彩文章第一时间推送 8月31日，甫康生物科技（上海）股份有限公司（下称"甫康药业"）向港交所递交主板上市申请，农银国际、 民银资本、复星国际资本为其联席保荐人。 制图：佘诗婕 最大客户贡献99% 甫康药业成立于2015年，专注于采取商业化与临床开发并重的双轨策略，专注于开发癌症相关疾病治疗领域 的突破性疗法，同时兼顾针对病毒和衰老疾病领域创新药物的开发及商业化。 公司的核心产品包括CVL009和CVL218，前者为2.4类改良新药，公司目前正在就CVL009针对携带罕见 HER1（是表皮生长因子受体家族成员之一）突变的非小细胞肺癌患者、HER2阳性胃癌脑转移患者以及与卡 培他滨联合疗法进行第二期临床试验，后者是一种适用于治疗晚期实体瘤的新型第二代高选择性PARP抑制。 截至2025年8月22日，甫康药业已建立由一项商品化产品汉奈佳®、两项核心产品、两项关键产品及12项其 他在研候选药物组成的多元化产品组合。该等16项候选药物中，5项处于临床I期╱II期开发阶段，7项处于临 床前开发阶段，4项为仿制药候选药物。公司的在研项目主要围绕肿瘤治疗、抗病毒及抗衰老领域，而核心产 品虽以肿瘤治疗领 ...

Market Overview - On September 3, the Shanghai and Shenzhen indices opened high but showed weak performance, particularly the Shanghai Composite Index, which indicated a potential top formation [2] - The market saw 823 stocks rise and 4560 stocks fall, with a trading volume of 239.57 billion yuan, down approximately 51.67 billion yuan from the previous day [2] - The military industry sector led the decline, while the photovoltaic sector rebounded, and gold strengthened due to the depreciation of the US dollar [2] Market Sentiment - The net outflow of funds exceeded 100 billion yuan, indicating a continuous withdrawal of profit-taking funds from the market, which poses a risk [2] - The market's profitability indicator showed a poor performance with a profit-making effect of only 0.69% and a high failure rate of 52% for stocks hitting the limit up, suggesting a challenging environment for investors [3] Stock Performance - The market saw a lack of cohesion in the stock performance, with only one stock reaching a high of 9 consecutive boards, indicating a fragmented market and increasing risks [3] - Recent strong selling pressure and reduced trading volume suggest that the market may continue to decline, particularly for stocks that have risen significantly [3] Investment Strategy - Investors are advised to remain cautious and protect their capital, avoiding stocks that are showing signs of weakness and waiting for the market to stabilize before targeting potential upward sectors [3]

Core Viewpoint - China Shipbuilding Industry Corporation (China Shipbuilding) will absorb and merge with China Shipbuilding Heavy Industry Company (China Heavy Industry), leading to the termination of the latter's A-share listing by September 5, 2025, without entering a delisting transition period [1][12]. Group 1: Merger Details - The merger will involve issuing shares at a price of 37.84 yuan per share, with a swap ratio of 1 share of China Heavy Industry for 0.1339 shares of China Shipbuilding, amounting to a total transaction value of 115.15 billion yuan [4]. - The combined entity will have total assets exceeding 400 billion yuan, making it the largest publicly listed shipbuilding company globally [7]. Group 2: Financial Performance - For the first half of 2025, China Heavy Industry reported revenue of 32.62 billion yuan, a year-on-year increase of 47.56%, and a net profit of 1.75 billion yuan, up 227.07% [5]. - In the same period, China Shipbuilding achieved revenue of 40.33 billion yuan, reflecting an 11.96% year-on-year growth, with a net profit of 2.95 billion yuan, increasing by 108.59% [6]. Group 3: Timeline of Events - The merger plan was first disclosed in September 2022, with approval from the State-owned Assets Supervision and Administration Commission in January 2023 [9][10]. - The merger project received approval from the Shanghai Stock Exchange's merger and acquisition committee on July 4, 2023 [11]. - China Heavy Industry submitted its application for voluntary delisting on August 14, 2023, and received the delisting decision on August 29, 2023 [12].